Agents Increasing Serum Potassium has 6 known drug interactions based on U.S. FDA drug labeling data. 3 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Irbesartan, Losartan Potassium, Losartan Potassium And Hydrochlorothiazide. Patients taking Agents Increasing Serum Potassium should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 6
- Major
- 3
- Moderate
- 3
Major (3)
- Agents Increasing Serum Potassium + Irbesartan— Coadministration of irbesartan with drugs that raise serum potassium levels may result in hyperkalemia, sometimes severe…
- Agents Increasing Serum Potassium + Losartan Potassium— Coadministration may result in hyperkalemia. Monitor serum potassium in such patients.
- Agents Increasing Serum Potassium + Losartan Potassium And Hydrochlorothiazide— Risk of hyperkalemia when coadministered with losartan. Monitor serum potassium in such patients.
Moderate (3)
- Agents Increasing Serum Potassium + Finerenone— More frequent serum potassium monitoring is warranted with concomitant use due to increased risk of hyperkalemia.
- Agents Increasing Serum Potassium + Olmesartan Medoxomil And Hydrochlorothiazide— Coadministration may result in hyperkalemia. Monitor serum potassium in patients receiving concomitant potassium-raising…
- Agents Increasing Serum Potassium + Sparsentan— Increased risk of hyperkalemia. Monitor serum potassium frequently.